Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

Pamiparib + Temozolomide

Stage Phase 1

Sponsor University of California, San Francisco

Modality small molecule

Class PARP inhibitor

Target PARP1/2

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/api/v2/studies?query.cond=glioma&query.term=IDH

ClinicalTrials.gov API v2: IDH-mutant glioma interventional records plus 34 individual records, retrieved 11.07.2026 (registry fields as entered by sponsors)

Brief source I16

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03749187

A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

PNOC017

Registry NCT03749187

Phase Phase 1

Status Active, not recruiting

Enrollment 78

Start 2019-04-03

Primary completion 2026-06-30

Study completion 2029-07-30

Catalyst Primary completion. 06.30.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.